What is Rdx Bioscience?
Rdx Bioscience operates as a CAP-accredited and CLIA-certified clinical diagnostic laboratory, providing a comprehensive suite of testing services tailored to the needs of healthcare providers and risk-bearing organizations. The company distinguishes itself by integrating proprietary algorithms with laboratory interventions, such as genetic testing and medication adherence assays, to support ACOs, Medicare STARs, and MIPS initiatives. By focusing on the shift toward risk-based contracting, Rdx Bioscience empowers clinicians to deliver high-quality care while navigating the complexities of chronic disease management and state-based Medicaid incentive programs. Its market position is defined by a service-oriented model that prioritizes clinical outcomes and operational efficiency for its partners.
How much funding has Rdx Bioscience raised?
Rdx Bioscience has raised a total of $1.8M across 2 funding rounds:
Debt
$1M
Debt
$750K
Debt (2020): $1M with participation from PPP
Debt (2021): $750K led by PPP
Key Investors in Rdx Bioscience
PPP
Public-Private Partnership
What's next for Rdx Bioscience?
With the recent influx of capital, Rdx Bioscience is well-positioned to accelerate its innovation roadmap, particularly in the development of advanced diagnostic assays that address the rising prevalence of chronic health conditions. The company's strategic focus will likely remain on enhancing its proprietary data analytics capabilities to further assist delegated medical groups in achieving quality benchmarks. As the healthcare landscape continues to prioritize value-based care, Rdx Bioscience is poised to expand its footprint by offering scalable laboratory solutions that reduce hospital re-admissions and optimize care coordination. Future growth will be driven by the continued adoption of its diagnostic programs, which serve as a competitive advantage for health organizations operating under risk-bearing contracts.
See full Rdx Bioscience company page
